We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Indian government is planning to relaunch a program that would sell hundreds of quality generic drugs at low cost under its own label, Jan Aushadhi. Read More
The court ruled that a brand drugmaker’s payment to settle an infringement case that delays generic competition can support a pay-for-delay claim. Read More
The FDA is creating a simple, one-step process for physicians to gain access to experimental drugs for patients facing terminal, untreatable conditions. Read More
Colorado lawmakers have introduced a biosimilar substitution bill that closely mirrors at least one aspect of compromise language unveiled by industry leaders in December — elimination of prescriber notification in favor of entering a switch into an electronic database. Read More
Actavis will become the UK’s largest generics supplier once its roughly $461 million acquisition of Auden Mckenzie closes in the first quarter of this year. Read More